Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
BioMarin (BMRN; SWX:BMRN) SG Cowen Phil Nadeau Other In line
Nadeau raised his FY04 revenue estimate to $4.7M from $4.6M but lowered his FY05 revenue estimate to $34.8M from $45M due to recently approved generic versions of Orapred for asthma in children. BMRN closed Friday at $3.99, down $0.14 on the week.
Cephalon (CEPH) SG Cowen Eric Schmidt Other NA
Schmidt

Read the full 700 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE